These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37880052)

  • 1. Ion homeostasis in diabetic kidney disease.
    Hu H; Liang W; Ding G
    Trends Endocrinol Metab; 2024 Feb; 35(2):142-150. PubMed ID: 37880052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
    Gohda T; Murakoshi M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.
    Gan T; Song Y; Guo F; Qin G
    Mol Biol Rep; 2022 Nov; 49(11):10915-10924. PubMed ID: 36002651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Diabetic Kidney Disease: Current and Future.
    Yamazaki T; Mimura I; Tanaka T; Nangaku M
    Diabetes Metab J; 2021 Jan; 45(1):11-26. PubMed ID: 33508907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells.
    Morita M; Kanasaki K
    Diabetes Metab; 2020 Oct; 46(5):353-361. PubMed ID: 32891754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CREDENCE: Significant Victory for Diabetic Kidney Disease.
    Verma A; Patel AB; Upadhyay A; Waikar SS
    Trends Endocrinol Metab; 2020 Jun; 31(6):391-393. PubMed ID: 32327275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New progress in drugs treatment of diabetic kidney disease.
    Wang J; Xiang H; Lu Y; Wu T; Ji G
    Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors.
    Guo W; Li H; Li Y; Kong W
    Biomed Pharmacother; 2023 Sep; 165():115025. PubMed ID: 37385209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
    [No Abstract]   [Full Text] [Related]  

  • 12. A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.
    Kume S; Maegawa H
    J Diabetes Investig; 2022 May; 13(5):765-767. PubMed ID: 35029051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and the kidney.
    Chowdhury TA; Ali O
    Clin Med (Lond); 2021 Jul; 21(4):e318-e322. PubMed ID: 35192470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
    Kashihara N; Kidokoro K; Kanda E
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):112-118. PubMed ID: 31725011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.
    Garofalo C; Borrelli S; Liberti ME; Andreucci M; Conte G; Minutolo R; Provenzano M; De Nicola L
    Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Winiarska A; Knysak M; Nabrdalik K; Gumprecht J; Stompór T
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
    van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
    Mima A
    Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions.
    Tommerdahl KL; Kula AJ; Bjornstad P
    Expert Opin Pharmacother; 2023 Jun; 24(8):913-924. PubMed ID: 37071054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.